Zobrazeno 1 - 10
of 21
pro vyhledávání: '"José Figueras-Aloy"'
Autor:
F. Martinón-Torres, José Figueras-Aloy, M. Sánchez-Luna, Xavier Carbonell-Estrany, Manuel Sanchez-Solis, Itziar Oyagüez, R. Burgos-Pol
Publikováno v:
BMC Infectious Diseases, Vol 17, Iss 1, Pp 1-11 (2017)
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
BMC Infectious Diseases
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
BMC Infectious Diseases
Background This study aimed at estimating the efficiency of palivizumab in the prevention of Respiratory Syncytial Virus (RSV) infection and its sequelae in preterm infants (32day 1-35day 0weeks of gestational age –wGA-) in Spain. Methods A decisio
Autor:
John R. Fullarton, Xavier Carbonell-Estrany, Pamela G. Vo, Barry Rodgers-Gray, Katherine L. Gooch, José Figueras-Aloy
Publikováno v:
The Journal of Maternal-Fetal & Neonatal Medicine. 28:1133-1141
To evaluate the key risk factors for respiratory syncytial virus (RSV) hospitalisation in 32-35 weeks' gestational age (wGA) infants.Published risk factors were assessed for predictive accuracy (area under the receiver operating characteristic curve
Autor:
Katherine L. Gooch, Johannes G. Liese, Pamela G. Vo, John R. Fullarton, Marcello Lanari, Jean-Bernard Gouyon, Xavier Carbonell-Estrany, José Figueras-Aloy
Publikováno v:
Journal of Maternal-Fetal and Neonatal Medicine
Journal of Maternal-Fetal and Neonatal Medicine, Taylor & Francis, 2013, 26 (9), pp.926--931. ⟨10.3109/14767058.2013.765850⟩
Journal of Maternal-Fetal and Neonatal Medicine, Taylor & Francis, 2013, 26 (9), pp.926--931. ⟨10.3109/14767058.2013.765850⟩
International audience; OBJECTIVE: To assess the impact of household smoking and palivizumab prophylaxis on the risk of respiratory syncytial virus (RSV) hospitalisation in late-preterm (32-35 weeks' gestational age) infants. METHODS: Familial smokin
Publikováno v:
jpme. 40:685-691
Aim: The aim of this study was to examine whether the risk for respiratory syncytial virus (RSV)-related hospitalisation changes through the first year of life in infants of 32–35 weeks’ gestational age (wGA). Methods: Risk factors from the FLIP-
Autor:
Xavier Carbonell-Estrany, Iolanda Jordán-García, Inmaculada Ferrer-Codina, José Figueras-Aloy, Lilian Gómez-López, M. Dolors Salvia-Roiges, Rafael Jiménez-González, José-Manuel Rodríguez-Miguélez
Publikováno v:
American Journal of Perinatology. 24:331-338
Adhesion molecules may play a role in the evolution and severity of neonatal sepsis. The purposes of this study were to determine whether serum soluble intercellular adhesion molecule (ICAM)-1, vascular cell adhesion molecule (VCAM)-1, L-selectin, an
Autor:
Cristina Fernandez Perez, Jesús Pérez Rodríguez, Vicente Roqués Serradilla, José Figueras-Aloy, Rafael Jiménez Gonzalez, Manuel Moro Serrano, José Quero Jiménez
Publikováno v:
American Journal of Perinatology. 22:441-448
The purpose of this study was to analyze the influence of antenatal glucocorticoid therapy (AGT) on mortality and chronic lung disease (CLD) in surviving preterm infants 23 to 28 weeks gestational age (WGA). This was a multicenter, prospective, obser
Publikováno v:
Pediatric Infectious Disease Journal. 23:S193-S201
Background: Prematurity is a proven risk factor for severe respiratory syncytial virus (RSV) infection. Prematurity leads to an increased need for, and duration of, hospital admission, intensive care, mechanical ventilation and supplemental oxygen, a
Publikováno v:
Pediatric Infectious Disease Journal. 23:815-820
Background and Objective:The aim of this study was to identify those risk factors most likely to lead to the development of RSV-related respiratory Infection and subsequent hospital admission among premature infants born at 33–35 WGA (FLIP study)Me
Publikováno v:
The Pediatric Infectious Disease Journal. 22:823-827
BACKGROUND Respiratory syncytial virus (RSV) is a major cause of hospitalization in preterm infants and infants with chronic lung disease (CLD). Palivizumab, a humanized monoclonal antibody, was approved in Europe in 1999 as prophylaxis against sever
Autor:
José Quero, José Figueras-Aloy, Gerardo Bustos, Jose M. Fraga, Manuel García del Río, Xavier Krauel, Mercedes Zapatero, Eduardo Doménech, Eduardo Narbona, Angel Cotero, Alfredo García-Alix, Xavier Carbonell-Estrany, Vicente Roques, Sofia Salas HernÁndez, Jose B. LÓpez Sastre, Luz GarcÍa GarcÍa
Publikováno v:
The Pediatric Infectious Disease Journal. 19:592-597
Objective. To collect data on hospitalization for respiratory syncytial virus (RSV) infections and presumptive risk factors for rehospitalization among premature infants in Spain. Design. Observational, prospective, longitudinal, multicenter study. S